Universal Beteiligungs und Servicegesellschaft mbH Lowers Holdings in Integer Holdings Corporation (NYSE:ITGR)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has reduced its stake in Integer Holdings Corporation by 32.1%, now holding $4.77 million worth of shares after selling 19,129 shares.
• Analysts have mixed views on Integer's stock, with target prices ranging from $132.00 to $145.00 and a consensus rating of "Moderate Buy."
• CEO Joseph W. Dziedzic significantly decreased his stock ownership by selling 338,975 shares, representing an 87.82% drop in his position.

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 32.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,405 shares of the medical equipment provider's stock after selling 19,129 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Integer worth $4,768,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. AdvisorNet Financial Inc purchased a new stake in Integer during the 1st quarter valued at $28,000. Opal Wealth Advisors LLC purchased a new stake in Integer during the 1st quarter valued at $28,000. Bessemer Group Inc. boosted its stake in shares of Integer by 73.1% in the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after buying an additional 125 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after buying an additional 279 shares during the last quarter. Finally, Contravisory Investment Management Inc. boosted its stake in shares of Integer by 103.9% in the 1st quarter. Contravisory Investment Management Inc. now owns 1,413 shares of the medical equipment provider's stock worth $167,000 after buying an additional 720 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Integer Price Performance

NYSE:ITGR traded up $0.11 on Thursday, reaching $108.87. 83,430 shares of the company's stock traded hands, compared to its average volume of 496,715. Integer Holdings Corporation has a 12 month low of $104.93 and a 12 month high of $146.36. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. The stock has a 50-day simple moving average of $118.08 and a 200-day simple moving average of $123.21. The firm has a market cap of $3.81 billion, a PE ratio of 47.84, a P/E/G ratio of 0.86 and a beta of 0.98.

Integer (NYSE:ITGR - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%. The firm had revenue of $476.00 million during the quarter, compared to the consensus estimate of $464.37 million. During the same period last year, the firm posted $1.30 earnings per share. The company's revenue for the quarter was up 11.4% compared to the same quarter last year. Equities research analysts forecast that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

ITGR has been the topic of a number of research reports. Wells Fargo & Company dropped their price target on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Raymond James Financial dropped their price target on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research note on Friday, July 25th. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and raised their price target for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. Truist Financial dropped their price target on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. Finally, Wall Street Zen upgraded Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Integer presently has an average rating of "Moderate Buy" and a consensus price target of $140.25.

Insider Activity

In related news, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares in the company, valued at approximately $2,260,856.78. This trade represents a 43.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.16% of the company's stock.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.